Antibody Drug Conjugates Contract Manufacturing Market to reach US$6.31bn by 2036
25 September 2026.
Visiongain has released its new Antibody Drug Conjugates Contract Manufacturing Market Report 2026-2036, forecasting that the global market will reach US$6.31bn by 2036 from US$2.14bn in 2026.
The market is forecast to expand at a compound annual growth rate (CAGR) of 11.4% between 2026 and 2036, driven by the continued expansion of the ADC pipeline, rising commercial manufacturing requirements, and growing CDMO investment in bioconjugation and high-potency manufacturing capacity.
Key Market Growth Drivers & Industry Transformations
Increasing Outsourcing of Complex ADC Manufacturing: ADC manufacturing requires specialist capabilities across biologics production, linker and payload chemistry, high-potency containment, conjugation, purification and sterile drug-product manufacturing. Pharmaceutical and biotechnology companies are using CDMOs to access established GMP infrastructure and technical expertise without constructing dedicated facilities for every programme. On 16 March 2026, Piramal Pharma Solutions announced that its Grangemouth facility had completed its 1,500th ADC batch – a commercial oncology ADC – providing direct evidence that outsourced ADC production is extending beyond development and clinical supply into recurring commercial manufacturing.
Rising Approvals and Commercial Production Requirements: The progression of ADC candidates from clinical development to regulatory approval is increasing demand for commercial-scale contract manufacturing. Commercial production introduces more extensive requirements for process characterisation, cleaning validation, analytical testing, stability programmes and regulatory inspection readiness. These requirements favour experienced CDMOs with established high-potency containment, bioconjugation and aseptic manufacturing capabilities. Demand increases further when approved ADCs enter additional indications and geographic markets.
Growing Investment in Bioconjugation and HPAPI Capacity: CDMOs are investing in bioconjugation suites, high-potency API facilities, analytical laboratories and sterile drug-product capacity to address rising ADC demand. On 21 September 2026, WuXi XDC held a ceremony marking the GMP release of its first overseas manufacturing site in Singapore. The approximately 25,000-square-metre site integrates antibody-intermediate, conjugated drug-substance and sterile drug-product manufacturing, with BCM3 supporting batches of up to 2,000 litres and DP4 providing annual capacity for up to eight million liquid or lyophilised bioconjugate vials.
Expansion of ADC Manufacturing Capacity in Asia-Pacific: Asia-Pacific is becoming an increasingly important location for ADC development and manufacturing as regional capabilities extend beyond conventional biologics production into high-potency chemistry, bioconjugation and sterile drug-product services. On 5 February 2026, Samsung Biologics stated it planned to introduce ADC drug-product services in early 2027, adding to its existing conjugation-process development, analytical, formulation and drug-substance capabilities in South Korea.
What This Means for the ADC Contract Manufacturing Market
The ADC contract manufacturing market is entering a period of accelerating structural growth as the pipeline deepens, commercial approvals accumulate, and pharmaceutical companies increasingly rely on specialist CDMOs for high-potency manufacturing and integrated end-to-end services. CDMOs that combine scalable bioconjugation infrastructure, geographically distributed manufacturing networks, and proven regulatory performance across clinical and commercial programmes are best positioned to capture long-term value over the next decade.
Scope of the Visiongain Report
The 300+ page report provides robust quantitative and qualitative analysis across all key facets of the global ADC contract manufacturing market:
By Linker: Cleavable Linker; Non-Cleavable Linker.
By Service: Process / Cell-line Development; Analytical, Bioassay & QC; CGMP Conjugation & Drug-linker Manufacturing; Fill-finish and Packaging.
By Condition: Haematological Malignancies; Solid Tumours; Others.
By Scale of Operation: Clinical; Commercial.
By Regional & Country Markets: North America, Europe, Asia Pacific, Latin America, and MEA.
Competitive Landscape
The competitive environment is characterised by specialist bioconjugation CDMOs, integrated pharmaceutical manufacturers with dedicated ADC platforms, and large contract manufacturers expanding into high-potency biologics. Companies profiled in the report include:
- AbbVie, Inc.
- Abzena
- AGC Biologics
- Ajinomoto Bio-Pharma Services
- Axplora
- BSP Pharmaceuticals
- Cambrex
- CARBOGEN AMCIS
- Catalent, Inc. (Novo Holdings)
- Cerbios-Pharma SA
- CordenPharma
- Lonza Group AG
- Merck KGaA
- Oncotec Pharma Produktion GmbH
- Piramal Pharma Solutions
- Recipharm AB
- Samsung Biologics
- Sterling Pharma Solutions
- Thermo Fisher Scientific Inc. (Patheon Pharma Services)
- WuXi XDC
Recent Developments
- 21 Sep 2026 –Â WuXi XDC held a ceremony marking the GMP release of its first overseas manufacturing site in Singapore, following GMP release of its BCM3 and DP4 production lines in August 2026. The approximately 25,000-square-metre site integrates antibody-intermediate, conjugated drug-substance and sterile drug-product manufacturing, with DP4 providing annual capacity for up to eight million bioconjugate vials.
- 19 Feb 2026 –Â Lonza strengthened its Advanced Synthesis offering by fully integrating the ADC technology platform acquired through Synaffix, including GlycoConnect antibody-conjugation technology, HydraSpace polar-spacer technology and a growing portfolio of toxSYN linker-payloads. Lonza also expanded laboratory infrastructure and scale-up capabilities in Oss, the Netherlands.
- 5 Feb 2026 –Â Samsung Biologics stated it planned to introduce ADC drug-product services in early 2027, extending its existing conjugation-process development, analytical characterisation, formulation and drug-substance capabilities to cover additional stages of the ADC manufacturing chain.
Related Reports
- Biopharmaceuticals Contract Manufacturing Market 2026-2036
- mRNA Contract Manufacturing Market 2026-2036
- Protein Contract Manufacturing Market 2026-2036
- Peptide Contract Manufacturing Market 2026-2036
About Visiongain
Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.
Media Contact
press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com
